Chan Jeremy, Narayan Pradeep, Fudulu Daniel P, Dong Tim, Vohra Hunaid A, Angelini Gianni D
Department of Cardiac Surgery, Bristol Heart Institute, University of Bristol, Bristol, UK.
Department of Cardiac Surgery, Rabindranath Tagore International Institute of Cardiac Sciences, Narayana Health, India.
Eur J Cardiothorac Surg. 2025 Feb 4;67(2). doi: 10.1093/ejcts/ezaf033.
The last 2 decades have seen an incremental use of biological over mechanical prostheses. However, while short-term clinical outcomes are largely equivalent, there is still controversy about long-term outcomes.
All patients between the ages of 50 and 70 years undergoing elective/urgent isolated aortic valve replacement at our institute between 1996 and 2023 were included. Trends, early, and long-term outcomes were investigated.
A total of 1708 (61% male) patients with a median age of 63.60 (interquartile range: 58.28-67.0) years were included of which 1191 (69.7%) received a biological prosthesis. After inverse propensity score weighting, there were no short-term differences when comparing patients receiving biological and mechanical valves. However, patients who received mechanical prostheses had better long-term survival (P < 0.001). Sub-group analysis revealed that patients with biological size 19 mm prosthesis had the worst long-term survival. Patients with a size 21-mm mechanical prosthesis had better survival compared to both size 19-mm [hazard ratio (HR) 0.25, 95% confidence interval (CI) 0.17-0.37, P < 0.001], 21-mm (HR 0.33, 95% CI 0.23-0.48, P < 0.001) and 23-mm (HR 0.40, 95% CI 0.27-0.60, P < 0.001) biological prosthesis. Additionally, patients with severe patient-prosthesis mismatch exhibited the lowest survival rate compared to those with moderate or no (HR 1.56, 95% CI 1.21-2.00, P < 0.001).
Patients aged between 50 and 70 years with a mechanical aortic prosthesis had better long-term survival compared to those with a biological prosthesis. Our study underscores the need for a critical re-evaluation of prosthesis selection strategies in this age group.
在过去20年中,生物假体在使用上逐渐超过了机械假体。然而,尽管短期临床结果在很大程度上相当,但关于长期结果仍存在争议。
纳入1996年至2023年期间在我院接受择期/急诊单纯主动脉瓣置换术的所有50至70岁患者。研究了其趋势、早期和长期结果。
共纳入1708例(61%为男性)患者,中位年龄为63.60岁(四分位间距:58.28 - 67.0岁),其中1191例(69.7%)接受了生物假体。在进行逆概率评分加权后,比较接受生物瓣膜和机械瓣膜的患者时,短期没有差异。然而,接受机械假体的患者长期生存率更高(P < 0.001)。亚组分析显示,使用19毫米生物尺寸假体的患者长期生存率最差。与19毫米尺寸(风险比[HR] 0.25,95%置信区间[CI] 0.17 - 0.37,P < 0.001)、21毫米尺寸(HR 0.33,95% CI 0.23 - 0.48,P < 0.001)和23毫米尺寸(HR 0.40,95% CI 0.27 - 0.60,P < 0.001)的生物假体相比,使用21毫米机械假体的患者生存率更高。此外,与中度或无患者-假体不匹配的患者相比,严重患者-假体不匹配的患者生存率最低(HR 1.56,95% CI 1.21 - 2.00,P < 0.001)。
年龄在50至70岁之间的患者,使用机械主动脉假体的长期生存率高于使用生物假体的患者。我们的研究强调了对该年龄组假体选择策略进行严格重新评估的必要性。